The Ensign Group Acquires Skilled Nursing Facility in Texas

Acquires the real estate and operations of Windsor Rehabilitation and Healthcare, a 108-bed skilled nursing facility, located in Terrell, TX.

The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services.

Today they announced that it acquired the real estate and operations of Windsor Rehabilitation and Healthcare, a 108-bed skilled nursing facility, located in Terrell, TX. The acquisition was effective May 1, 2021.

“We are very excited to add another operation in North Texas and believe that this newer building is poised to do great things,” said Barry Port, Ensign’s Chief Executive Officer. “We will continue to look for opportunities in Texas and are confident that our local clusters are well prepared for this addition and for additional growth,” he added.

Kevin Niccum, President of Keystone Care LLC, Ensign’s Texas-based subsidiary, added “Given some of the extra safety protocols that were needed due to the pandemic, we had extra time to prepare for this transition and have been able to get to know the Windsor team.  We are very impressed with the whole group and look forward to combining our experience with theirs as we join in our efforts to become a helpful partner to the local healthcare community.”

This acquisition brings Ensign’s growing portfolio to 236 healthcare operations, 22 of which also include senior living operations, across thirteen states.  Ensign owns 95 real estate assets.  Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare-related businesses throughout the United States.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.